Abstract:Human CYP1B1 as one member in CYP1 family could catalyze the bioactivation of certain procarcinogens.It plays a pivotal role in the carcinogenic action of 17-β-estradiol.Recent knowledge relating to the high and consistent expression of this enzyme in various tumor organs and the involvement of it in anti-cancer drug resistance,make the inhibition of CYP1B1 as a new method in cancer prevention and therapy.Resveratrol,an inhibitor of CYP1B1,has been deemed as one of the potential chemopreventive trans-stilbenes.α-Naphthoflavone(ANF)as a strong and selective inhibitor of CYP1B1,has been employed for eliminating CYP1B1-mediated anti-cancer drug resistance in vitro.Taking ANF as a lead,α-(E)-styryl-4,5,8-trimethoxy naphthalene(Ⅰ1)and its derivatives(Ⅰ2-Ⅰ10)as the structural analogues of the lead were synthesized via the Horner-Wadsworth-Emmons reactions between phosphonates and 4,5,8-trimethoxy-1-naphthaldehyde.β-(E)-Styryl-1,4,8-trimethoxy naphthalenes(Ⅱ1-Ⅱ8)and β-(E)-styryl-1,4,5,8-tetramethoxy naphthalenes(Ⅲ1-Ⅲ8)were also prepared to examine the influence of the position of the styryl moiety on the naphthalene part of these new compounds towards CYP1B1 inhibition.All the candidates prepared were evaluated for their inhibitory effects on CYP1B1-mediated EROD activity.The results suggested that most of these new compounds were more potent inhibitors of human CYP1B1 enzyme than resveratrol.Compared with the lead,compounds Ⅰ2,Ⅰ8,Ⅲ2,Ⅲ4 exhibited much higher potency and selectivity towards CYP1B1 inhibition.The SARs analysis indicated that α-(E)-styryl-4,5,8-trimethoxy naphthalenes(Ⅰ)were stronger inhibitors than the corresponding β-(E)-styryl-1,4,8-trimethoxy naphthalenenes(Ⅱ)and β-(E)-styryl-1,4,5,8-tetramethoxy naphthalenes(Ⅲ).The introduction of 3′,4′,5′-OMe groups or a 4′-OMe substitution on the styryl moiety of Ⅰ,Ⅱ and Ⅲ,caused sharp decrease in their inhibitory effects.On the contrary,the derivatives with the 2′-OMe substitution(Ⅰ8,Ⅱ6,Ⅲ6)exhibited increased inhibitory potency.Meanwhile,4′-F analogues(Ⅰ2,Ⅱ2,Ⅲ2)showed more potent inhibition than the corresponding 4′-Cl and 4′-OMe analogues.Among the tested ones,Ⅰ2 exhibited the strongest inhibition effects with the IC50 value of 0.31 nmol · L-1.

Recent Research Progress on the CYP1B1 Inhibitors

Research on the CYP 1B1 Inhibitors As Anti-cancer Drugs

CYP1A inhibitors: Recent progress, current challenges, and future perspectives

Inhibitors and Prodrugs Targeting Cyp1: A Novel Approach in Cancer Prevention and Therapy

The Activation of Procarcinogens by CYP1A1/1B1 and Related Chemo-Preventive Agents: A Review

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Research on the Targeted Antitumor Prodrug Activated by Cytochrome P450 1A1 and 1B1

Effects of xenobiotics on CYP1 enzyme-mediated biotransformation and bioactivation of estradiol

Development of 2-arylbenzo[h]quinolone analogs as selective CYP1B1 inhibitors

Synthesis of styrylnaphthalenes as potent inhibitors of CYP1B1

Flavonoids and Naphthoflavonoids: Wider Roles in the Modulation of Cytochrome P450 Family 1 Enzymes.

Recent Researches on Anti-tumor Drug Development by Targeting Cytochrome P450

Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors

Progress in relationship of cytochrome P450 1A2 genetic polymorphism,substance metabolism and carcinogenesis

Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2

Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance

Development Of Benzochalcone Derivatives As Selective Cyp1b1 Inhibitors And Anticancer Agents

Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer

Recent Advances in the Research of P-glycoprotein Inhibitors.

CYP450:a New Hot-spot in Tumor Research

Design and synthesis of new alfa-naphthoflavanones as potent and selective CYP1B1 inhibitors